迪哲（江苏）医药股份有限公司

Dizal Pharmaceutical Co., Ltd, with stock code 688192, is a pioneering biopharmaceutical enterprise dedicated to the research, development, and commercialization of innovative therapies for oncology and immunological disorders. The company adheres to a core principle of original innovation, aiming to introduce first-in-class drugs and transformative treatment approaches to address unmet global clinical needs. Leveraging its industry-leading platform in translational science and new drug molecule design & screening, Dizal has constructed a robust product pipeline consisting of five globally competitive assets. Two of these assets are currently advancing through pivotal global clinical trials, with one having received regulatory approval for market entry.